Literature DB >> 17573297

The process used by surrogate decision makers to withhold and withdraw life-sustaining measures in an intensive care environment.

Michael H Limerick1.   

Abstract

PURPOSE/
OBJECTIVES: To understand the process used by surrogate decision makers who have chosen to withhold and withdraw life-sustaining measures in intensive care units (ICUs).
DESIGN: Grounded theory.
SETTING: Multihospital system in central Texas. SAMPLE: 17 surrogates who decided to withhold and withdraw life-sustaining measures from patients with a variety of diagnoses, including cancer.
METHODS: Surrogates were identified by review of charts of patients in ICUs. Interviews were recorded on audiotape and analyzed using the process of constant comparison. Saturation of data occurred when no new themes emerged. MAIN RESEARCH VARIABLE: The surrogate decision-making process.
FINDINGS: Domains and their respective themes included: (a) the personal domain: rallying family support, evaluating the patient's past and present condition, and viewing past and future quality of life; (b) the ICU environment domain: chasing doctors, developing relationships with the healthcare team, and confirming probable medical outcomes; and (c) the decision domain: arriving at a new belief, getting alone to make the decision, and communicating the decision.
CONCLUSIONS: Surrogates use a definite process to make decisions regarding withholding and withdrawing life-sustaining measures for patients in ICUs. IMPLICATIONS FOR NURSING: The results reveal opportunities for healthcare providers to improve education and change practice when supporting surrogates. Additional opportunities exist for further research to expand nursing knowledge related to end-of-life issues.

Entities:  

Mesh:

Year:  2007        PMID: 17573297     DOI: 10.1188/07.ONF.331-339

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  8 in total

1.  Examining the root cause of surrogate conflicts in the intensive care unit and general wards.

Authors:  Allison Neyhart Rubin; Katrina A Bramstedt
Journal:  Monash Bioeth Rev       Date:  2010-03

2.  I don't want to be the one saying 'we should just let him die': intrapersonal tensions experienced by surrogate decision makers in the ICU.

Authors:  Yael Schenker; Megan Crowley-Matoka; Daniel Dohan; Greer A Tiver; Robert M Arnold; Douglas B White
Journal:  J Gen Intern Med       Date:  2012-07-28       Impact factor: 5.128

3.  Conceptualizing surrogate decision making at end of life in the intensive care unit using cognitive task analysis.

Authors:  J Nicholas Dionne-Odom; Danny G Willis; Marie Bakitas; Beth Crandall; Pamela J Grace
Journal:  Nurs Outlook       Date:  2014-10-13       Impact factor: 3.250

4.  Nurse-led intervention to improve surrogate decision making for patients with advanced critical illness.

Authors:  Douglas B White; Sarah Martin Cua; Roberta Walk; Laura Pollice; Lisa Weissfeld; Seoyeon Hong; C Seth Landefeld; Robert M Arnold
Journal:  Am J Crit Care       Date:  2012-11       Impact factor: 2.228

Review 5.  Ethical frameworks for surrogates' end-of-life planning experiences.

Authors:  Hyejin Kim; Janet A Deatrick; Connie M Ulrich
Journal:  Nurs Ethics       Date:  2016-08-03       Impact factor: 2.874

6.  Nursing Roles and Strategies in End-of-Life Decision Making in Acute Care: A Systematic Review of the Literature.

Authors:  Judith A Adams; Donald E Bailey; Ruth A Anderson; Sharron L Docherty
Journal:  Nurs Res Pract       Date:  2011-10-02

7.  Concerns of surrogate decision makers for patients with acute brain injury: A US population survey.

Authors:  David Y Hwang; Andrea K Knies; David Mampre; Stanislav Kolenikov; Marci Schalk; Heather Hammer; Douglas B White; Robert G Holloway; Kevin N Sheth; Liana Fraenkel
Journal:  Neurology       Date:  2020-04-27       Impact factor: 11.800

8.  A scoping review of family experience and need during end of life care in intensive care.

Authors:  Maureen Coombs
Journal:  Nurs Open       Date:  2015-03-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.